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Fractionated stereotactic radiotherapy (FSRT) in the management of pituitary adenomas
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Introduction. Pituitary adenomas represent 10–20% of all intracranial tumors and are mostly hormone-secreting (about 75%).
Endoscopic Endonasal Transsphenoidal Resection (EETR) is themainstay treatment of symptomatic cases or refractory tomedical
therapy and FSRT is often an integral part of postoperative treatment.
Purpose. The aim of this study is to evaluate the efﬁcacy and safety of SFRT in pituitary adenomas.
Methods and materials. Between December 2009 and February 2013, 10 patients with pituitary adenoma (6 males and 4 females)
treated with SFRT were assessed prospectively. Nine patients underwent primary surgery (8 transsphenoidal resection and 1
subfrontal craniotomy) and 1 was unresectable. Median gross tumor volume (GTV) was 3.4 cc (range 0.8–24.6). A median dose of
50Gy (range 48–50Gy) was prescribed to the 98% of PTV (GTV plus 2.5mm margin). Median maximal dose to organs at risk was
as follows: 48.75Gy to chiasm (range 34.5–50.9) and 48.5Gy to brainstem (range 15–53).
Results. Median age was 50.5 years (range 30–83). Six tumors (60%) were secretory (3 growth hormone, 2 adrenocorticotropic
hormone and 1 prolactin) and 4(40%) non secretory. SFRT was indicated for residual, recurrent and unresectable tumor in 8.1,
and 1 patient respectively. With a median time follow up of 11 months (range 8–25) tumor control rate was 100% (7 reduction
disease and 3 stable disease). Hormonal control was achieved in 2/10 patients. Postoperative panhypopituitarism (5) and visual
deﬁcit (4) remained the same after FSRT. None of 10 patients developed radiation induced toxicity according to CTCAE scale.
Conclusions. FSRT is a safe and effective treatment in residual or recurrent adenoma pituitary after resection surgery but long
term follow up is required to determine control in secretory tumors.
http://dx.doi.org/10.1016/j.rpor.2013.03.538
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Introduction. The role of whole brain irradiation (WBI) in the treatment of metastatic brain disease is controversial since data
available support, at least, no inferiority in overall survival and a better toxicity proﬁle in more selective and accurate irradiation
techniques. Moreover, the salvage irradiation after WBI failure remains challenging.
Purpose. The aim of our study was to assess the initial results provided by fractionated stereotactic radiotherapy (FSRT) for brain
metastasis treated in our institution.
Materials and methods. Between June 2010 and October 2012, 76 lesions from 43 patients with a single or multiple (up to 5)
intracranial metastasis were treated with FSRT as a primary treatment (24p), after surgical resection (7p) or after WBI failure
(13p). Fractionation schedules were 7×5Gy (n=28) and 5×5Gy (n=15) when WBI or surgery has been performed prior to FSRT.
Planning target volume enclosed the tumour or tumour resection cavity with a safety margin of 2–3 mm. Treatment was delivered
by NovalisTM 6D or Hi-Art TomotherapyTM linacs. Daily ExacTracTM or megavoltage computerized tomography images were
obtained.
Results. Median overall survival was 6.7 months, and 12-months survival was 19%. Median disease free survival was 5.18 months.
Mean cause speciﬁc survival (CNS failure related) was 22.13 months. No correlation among RPA class and outcome was observed.
Neither lesions’ size nor primary tumour histology was predictor of survival. No patient demonstrated toxicity grade 2 or higher.
Conclusion. FSRT as a primary, postoperative or salvage treatment is a feasible and well tolerated approach for the management
of single or multiple brain metastasis that could provide an effective treatment decreasing late toxicity related with WBI. Further
research is needed to establish a comparison with WBI toxicity results in long term survivors.
http://dx.doi.org/10.1016/j.rpor.2013.03.539
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Introduction. Stereotactic radiosurgery (SRS) has become increasingly used for treatment of brain metastases. A non-invasive
mask system plus Image Guided Radiotherapy (IGRT) is a very attractive and comfortable alternative.
Objective. To assess the clinical outcomes of frameless SRS for brain metastases using IGRT.
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Patients and methods. In ONCOSUR and CROASA between January 2010 and December 2012 we have treated 16 patients (50%
female) with 45 brain metastases and mean age of 53.63 years (33–68). A total of 21 treatments have been performed. Our GTV
margin was of 2–3mm. We have evaluated clinical, therapeutic data and acute toxicity.
Results. Primary tumorswere 7 breasts, 3melanomas, 5 lungs, and 1 esophagus. Only 6 patientswere also treatedwithwhole brain
radiotherapy (WBRT). The radiotherapy techniques used were: 15 Volume Modulated Arc Therapy (VMAT); 1 Intense Modulated
Therapy Step and Shoot (IMRT S-S); 1 Dynamic Arc Therapy (DART); and 4 3D Conformal Radiotherapy (3DCRT). The hipofrac-
tionated schemes more used were: 6Gy×6 fx (4 cases) and 10Gy×3 fx (6 cases). All patients received 2 fx per week. A variable
positioning accuracy of 1–4 mm has been reported for frameless stereotactic systems. In our series, IGRT repositioning mean
accuracy was: X=0.18 mm (0.01–0.44); Y=0.23mm (0.06–0.66); and Z=0.20mm (0.01–0.40). Acute side effects were not detected.
With a mean follow-up of 10.35 months (2–30), 6 patients are alive, and 10 are died. The causes of death were progression in:
brain 2 patients (no WBRT); lung 3 patients; liver 1 patient; unknown 3 patients and general deterioration 1 patient.
Conclusions. Frameless SRS is an effective and comfortable treatment in the management of brain metastases. Non-invasive mask
ﬁxation system plus IGRT is associated with a high repositioning accuracy with no errors up to 3mm.
http://dx.doi.org/10.1016/j.rpor.2013.03.540
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Objective. Craniopharingyoma is a sellar region neoplasm. Although histologically benign, it may cause visual and endocrino-
logical alterations and it has tendency to develop cysts and a high recurrence rate, representing a clinical challenge. Treatment is
not standardized. Therapeutic options being open or transsphenoidal surgery, cyst drainage, external or intralesional radiation
therapy and radiosurgery, even chemotherapy. To achieve better tumor control and reduce iatrogenesis (panhypopituitarism,
optic pathway lesion, hypothalamic lesion), there is a tendency towards management with surgery followed by irradiation of the
remaining tumor, treatment that is superior to surgery alone. We present our experience with Gamma-Knife radiosurgery as the
radiation treatment of choice.
Methods and patients. A retrospective review of the 49 cases of craniopharyngioma treated between 1993 and 2010 has been
performed. 16 of those patients were children (age under 15 years). Mean age was 32 years (ranged: 3–69). Forty four cases had
undergoneoneor variousprevious surgeries. 6 patientshad receivedprevious radiation therapyand1had received chemotherapy.
In 8 patients a stereotactic drainage of cysts was performed in concomitance with radiosurgery. Clinically, 26 patients had
hormonal alterations and 46 patients had visual symptoms.
Results. After an average follow-up of 45 months. 4 patients needed further treatment (surgery or chemotherapy) and only
1 experienced tumor progression in the long term. 97% of the patients showed clinical improvement or stabilization. Visual
impairments tend to improve, whether immediately or subsequently, while hormonal alterations usually persist. In 17% cyst
drainage was necessary to improve delayed worsening of visual impairment without solid tumor progression.
Conclusion. In the context of a multi-disciplinary approach to craniopharyngioma, Gamma-Knife radiosurgery offers excellent
long-term tumor control, without the signiﬁcant side-effects of other treatments. The results we present are comparable and add
further experience to other published series. Gamma-Knife radiosurgery is a simple and well tolerated technique with results
that can be reproduced worldwide and without interference with other procedures that may be necessary during the course of
the disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.541
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Introduction. Three techniques have been developed to reduce SBRT toxicity: tracking, gating and diaphragmatic compression.
eXaCradle changes that paradigm.
Purpose. The eXaCradle reduces SBRT movements. We want to show the high precision SBRT using eXaCradle, slow-CT and
ConeBeamCT.
Methods and materials. We work with eXaCradle that combines 8 points of compression that give an enormous quantity of degrees
of freedom to customize the compression of every patient, to every tumor. The following procedure is carried out: (a) A Slow-CT of
patient inside the eXaCradle is acquired without any type of compression and in free breathing. (b) On the movement blurring the
combination of compressions most according to the manufacturer recommendations is decided. (c) A new Slow-CT* is acquired.
(d) A third hold breathing CT is acquired. (e) Organs at risk and tumor must be contouring on the third CT. (f) The third CT and the
